Healthcare stocks were advancing pre-bell Tuesday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.1% and the iShares Biotechnology ETF (IBB) 0.3% higher.

Iovance Biotherapeutics (IOVA) stock was up more than 18% after the company raised its full year 2026 total revenue guidance to a range of $410 million to $420 million, from its prior outlook of $350 million to $370 million.

UniQure (QURE) shares were down more than 47% after the company said additional data from its ongoing phase 1/2 studies of AMT-130 in Huntington's disease showed less pronounced benefits at 48 months.

Pharming Group (PHAR) has appointed chief commercial officer Leverne Marsh and chief financial officer Kenneth Lynard as interim co-chief executive officers, the company said. Pharming Group stock was down more than 3% pre-bell.